Novo Nordisk-backed biopharmaceutical company MapLight files for U.S. IPO.

date
20/09/2025
On September 19th local time, MapLight Therapeutics, a clinical-stage biopharmaceutical company supported by Novo Nordisk, applied for a US IPO. The documents show that the company's flagship candidate products include two drugs for the treatment of schizophrenia and psychotic disorders in Alzheimer's disease.
Latest
See all latestmore